DI Mobile Menu

Search form


Epix completes study enrollment

Epix completes study enrollment

Contrast media developer Epix Medical has completed enrollment in the second of two phase III trials designed to detect peripheral vascular disease in the aortoiliac arteries using the company¹s new blood pool MR agent, MS-325. The company expects to complete a review of the data and release results in spring 2003. Positive study results from the first trial were reported last March at the annual American College of Cardiology meeting. Epix continues to enroll patients in the remaining two phase III clinical trials aimed at detecting peripheral vascular disease in the renal and pedal arteries. Enrollment in these trials should be completed in the first quarter of 2003. Epix plans to file a new drug application with the FDA for MS-325 approximately six months after enrollment is completed.


Loading comments...

By clicking Accept, you agree to become a member of the UBM Medica Community.